BSX vs NVS
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | BSX | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $51.19 | $154.61 | |
| Market cap as of 2026-08-12 | $74.2B | $230.6B | |
| P/E as of 2026-08-12 | 20.00 | 22.36 | BSX lower |
| PEG as of 2026-08-12 | 0.44 | 3.66 | BSX lower |
| Net margin as of 2026-08-12 | +17.5% | +22.5% | NVS higher |
| Gross margin as of 2026-08-12 | +69.8% | +75.0% | NVS higher |
| Operating margin as of 2026-08-12 | +19.8% | +29.9% | NVS higher |
| ROE as of 2026-08-12 | +14.9% | +29.9% | NVS higher |
| ROA as of 2026-08-12 | +8.3% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-12 | 0.43 | 1.18 | BSX lower |
| Revenue growth (YoY) as of 2026-08-12 | +13.5% | +3.3% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | n/a | |
| Dividend yield as of 2026-08-12 | n/a | +2.9% | |
| Beta as of 2026-08-12 | 0.58 | 1.18 | |
| 1-year return as of 2026-08-11 close | -50.2% | +30.4% | NVS higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.